Contact Dermatitis preclinical contract research

proposal-button

talk-scientist

toolbox

read-blog

Imiquimod-induced Psorasis: preclinical efficacy

Imiquimod (IMQ) is a TLR7/8 ligand as well as a potent immune activator. It is most commonly known for its anti-viral and anti-tumor applications, however when applied to the skin, it can induce and exacerbate psoriasis. Therefore, it can serve as a preclinical model for studying the pathogenic mechanisms in psoriasis-like dermatitis, which include an influx of various immune cells as well as hyperplasia of the epidermis.

Application of IMQ cream produces the following characteristics:

  • erythema, scaling and thickening on the back
  • increase in ear thickness
  • histological plaque type psoriasis
  • infiltration of mononuclear cells, dentritic cells, T cells and neutrophils